PITCHES is a Phase III trial in IntrahepaTic CHolestasis of pregnancy to Evaluate urSodeoxycholic acid (UDCA) in improving perinatal outcomes.
The purpose of the Clinical trial is to provide definitive evidence for (or against) a role for UDCA in ameliorating adverse perinatal outcomes.
The trial is a masked placebo-controlled randomised trial to evaluate UDCA vs. placebo in women with ICP between 20+0 to 40+6 weeks' gestation. The trial will be conducted at 30 centres across the UK and recruitment will run for approximately 39 months.
- EudraCT No.:
- REC Reference:
- Clinical Trials Unit:
- National Perinatal Epidemiology Unit CTU
- Co-sponsored by Kings College London and Guy's & St Thomas' NHS Foundation Trust
- The NIHR Efficacy and Mechanism Evaluation (EME) Programme
- Duration of Study:
- Recruitment to end in August 2018
UDCA 1g daily (500mg bd), increased in increments of 500mg per day every 3-14 days if there is no biochemical or clinical improvement, based on clinical decision, to a maximum of 2g per day. The dose of IMP may be reduced to 500mg daily. Administered orally as Ursofalk tablets each containing 500mg UDCA or matching placebo.
The primary short term objective of the trial is to determine if UDCA treatment of women with ICP between 20+0 to 40+6 weeks of gestation reduces the following adverse perinatal outcomes up to infant hospital discharge:
- In utero fetal death after randomisation
- Known neonatal death up to 7 days
- Preterm delivery (less than 37 weeks’ gestation)
- Neonatal unit admission for at least 4 hours
The secondary objectives of the trial are to:
- Investigate the effect of the intervention on other maternal and neonatal short-term outcomes.
- Assess the impact of both management strategies on health economic outcomes.
If you would like to contact the trial team, please email email@example.com.